Prepulse inhibition of the startle reflex in schizophrenia remains stable with short-term quetiapine

European Psychiatry

Volumn 26, Issue 5, 2011, Pages 271-275

  Molina, V ^a,b   Lopez D E ^b   Villa, R ^a   Perez J ^a   Martin C ^a   Ballesteros, A ^a   Cardoso, A ^b   Sancho, C ^c  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Prepulse inhibition; Quetiapine; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG TOLERANCE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; MALE; POSITIVE AND NEGATIVE SYMPTOMS SCALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; SCHIZOPHRENIA; SEX RATIO; SHORT COURSE THERAPY; SMOKING; STARTLE REFLEX; TREATMENT DURATION;

ACOUSTIC STIMULATION; ADULT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; SCHIZOPHRENIA; SENSORY GATING; STARTLE REACTION;

EID: 79960445953     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2010.03.002     Document Type: Article

References (39)

1. Adler L.E., Olincy A., Cawthra E.M., McRae K.A., Harris J.G., Nagamoto H.T., et al. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry 2004, 161:1822-1828.
2. Auclair A.L., Galinier A., Besnard J., Newman-Tancredi A., Depoortere R. Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. Psychopharmacology (Berl) 2007, 193:45-54.
3. Bakshi V.P., Swerdlow N.R., Braff D.L., Geyer M.A. Reversal of isolation rearing-induced deficits in prepulse inhibition by seroquel and olanzapine. Biol Psychiatry 1998, 43:436-445.
4. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 1990, 47:181-188.
5. Duncan E., Madonick S., Chakravorty S., Parwani A., Szilagyi S., Efferen T., et al. Effects of smoking on acoustic startle and prepulse inhibition in humans. Psychopharmacology (Berl) 2001, 156:266-272.
6. Ellwanger J., Geyer M.A., Braff D.L. The relationship of age to prepulse inhibition and habituation of the acoustic startle response. Biol Psychol 2003, 62:175-195.
7. Filion D.L., Dawson M.E., Schell A.M. The psychological significance of human startle eyeblink modification: a review. Biol Psychol 1998, 47:1-43.
8. Geyer M.A., Braff D.L. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr Bull 1987, 13:643-668.
9. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001, 156:117-154.
10. Hamm A.O., Weike A.I., Schupp H.T. The effect of neuroleptic medication on prepulse inhibition in schizophrenia patients: current status and future issues. Psychopharmacology (Berl) 2001, 156:259-265.
11. Hill K., Mann L., Laws K.R., Stephenson C.M., Nimmo-Smith I., McKenna P.J. Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand 2004, 110:243-256.
12. Hollingshead A., Frederick R. Social stratification and psychiatric disorders. Am Soc Rev 1953, 18:163-189.
13. Honea R., Crow T.J., Passingham D., Mackay C.E. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J Psychiatry 2005, 162:2233-2245.
14. Jovanovic T., Szilagyi S., Chakravorty S., Fiallos A.M., Lewison B.J., Parwani A., et al. Menstrual cycle phase effects on prepulse inhibition of acoustic startle. Psychophysiology 2004, 41:401-406.
15. Kapur S., Zipursky R., Jones C., Shammi C.S., Remington G., Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000, 57:553-559.
16. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
17. Kumari V., Soni W., Sharma T. Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry 1999, 156:1046-1051.
18. Kumari V., Soni W., Mathew V.M., Sharma T. Prepulse inhibition of the startle response in men with schizophrenia: effects of age of onset of illness, symptoms, and medication. Arch Gen Psychiatry 2000, 57:609-614.
19. Kumari V., Gray J.A., Geyer M.A., ffytche D., Soni W., Mitterschiffthaler M.T., et al. Neural correlates of tactile prepulse inhibition: a functional MRI study in normal and schizophrenic subjects. Psychiatry Res 2003, 122:99-113.
20. Kumari V., Gray J.A., Guptaa P., Luscher S., Sharma T. Sex differences in prepulse inhibition of the acoustic startle response. Personal Individ Differ 2003, 35:733-742.
21. Kumari V., Aasen I., Sharma T. Sex differences in prepulse inhibition deficits in chronic schizophrenia. Schizophr Res 2004, 69:219-235.
22. Kumari V., Aasen I., Papadopoulos A., Bojang F., Poon L., Halari R., et al. A comparison of prepulse inhibition in pre- and postmenopausal women and age-matched men. Neuropsychopharmacology 2008, 33:2610-2618.
23. Leumann L., Feldon J., Vollenweider F.X., Ludewig K. Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia. Biol Psychiatry 2002, 52:729-739.
24. Mackeprang T., Kristiansen K.T., Glenthoj B.Y. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naive schizophrenic patients. Biol Psychiatry 2002, 52:863-873.
25. Oranje B., Van Oel C.J., Gispen-De Wied C.C., Verbaten M.N., Kahn R.S. Effects of typical and atypical antipsychotics on the prepulse inhibition of the startle reflex in patients with schizophrenia. J Clin Psychopharmacol 2002, 22:359-365.
26. Postma P., Gray J.A., Sharma T., Geyer M., Mehrotra R., Das M., et al. A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia. Psychopharmacology (Berl) 2006, 184:589-599.
27. Powell S.B., Young J.W., Ong J.C., Caron M.G., Geyer M.A. Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice. Behav Pharmacol 2008, 19:562-565.
28. Quednow B.B., Wagner M., Westheide J., Beckmann K., Bliesener N., Maier W., et al. Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine. Biol Psychiatry 2006, 59:536-545.
29. Quednow B.B., Wagner M., Mossner R., Maier W., Kuhn K.U. Sensorimotor gating of schizophrenia patients depends on catechol O-Methyltransferase Val158Met polymorphism. Schizophr Bull 2008, 36:341-346.
30. Shoemaker J.M., Pitcher L., Noh H.R., Swerdlow N.R. Quetiapine produces a prolonged reversal of the sensorimotor gating-disruptive effects of basolateral amygdala lesions in rats. Behav Neurosci 2003, 117:136-143.
31. Swerdlow N.R., Braff D.L., Geyer M.A. GABAergic projection from nucleus accumbens to ventral pallidum mediates dopamine-induced sensorimotor gating deficits of acoustic startle in rats. Brain Res 1990, 532:146-150.
32. Swerdlow N.R., Bakshi V., Geyer M.A. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 1996, 279:1290-1299.
33. Swerdlow N.R., Hartman P.L., Auerbach P.P. Changes in sensorimotor inhibition across the menstrual cycle: implications for neuropsychiatric disorders. Biol Psychiatry 1997, 41:452-460.
34. Swerdlow N.R., Bakshi V., Waikar M., Taaid N., Geyer M.A. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology (Berl) 1998, 140:75-80.
35. Swerdlow N.R., Braff D.L., Geyer M.A. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol 2000, 11:185-204.
36. Swerdlow N.R., Light G.A., Cadenhead K.S., Sprock J., Hsieh M.H., Braff D.L. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry 2006, 63:1325-1335.
37. Swerdlow N.R., Talledo J., Sutherland A.N., Nagy D., Shoemaker J.M. Antipsychotic effects on prepulse inhibition in normal 'low gating' humans and rats. Neuropsychopharmacology 2006, 31:2011-2021.
38. Swerdlow N.R., Sprock J., Light G.A., Cadenhead K., Calkins M.E., Dobie D.J., et al. Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia. Schizophr Res 2007, 92:237-251.
39. Wynn J.K., Green M.F., Sprock J., Light G.A., Widmark C., Reist C., et al. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res 2007, 95:134-142.